180 related articles for article (PubMed ID: 35031791)
21. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Patrì A; Fabbrocini G
J Am Acad Dermatol; 2020 Jun; 82(6):e221. PubMed ID: 32283237
[No Abstract] [Full Text] [Related]
22. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
Quek E; Tahir H; Kumar P; Hastings R; Jha R
Br J Hosp Med (Lond); 2021 Mar; 82(3):1-9. PubMed ID: 33792391
[TBL] [Abstract][Full Text] [Related]
23. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Million M; Roussel Y; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
[No Abstract] [Full Text] [Related]
24. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
Kim AHJ; Sparks JA; Liew JW; Putman MS; Berenbaum F; Duarte-García A; Graef ER; Korsten P; Sattui SE; Sirotich E; Ugarte-Gil MF; Webb K; Grainger R;
Ann Intern Med; 2020 Jun; 172(12):819-821. PubMed ID: 32227189
[TBL] [Abstract][Full Text] [Related]
25. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Nguyen TV
Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
[No Abstract] [Full Text] [Related]
26. [How the search for new SARS-CoV-2 therapies did hit scientific literature. Is it time now for new approaches?].
Addis A; Amato L
Epidemiol Prev; 2020; 44(5-6 Suppl 2):21-22. PubMed ID: 33412788
[No Abstract] [Full Text] [Related]
27. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.
Diotallevi F; Campanati A; Radi G; Luchetti MM; Benfaremo D; Tagliati C; Simonetti O; Offidani A
J Med Virol; 2021 Jan; 93(1):5-7. PubMed ID: 32691896
[No Abstract] [Full Text] [Related]
29. Guidelines should not pool evidence from uncomplicated and severe COVID-19.
White NJ; Strub-Wourgaft N; Faiz A; Guerin PJ
Lancet; 2021 Apr; 397(10281):1262-1263. PubMed ID: 33765411
[No Abstract] [Full Text] [Related]
30. Preprint Servers in Kidney Disease Research: A Rapid Review.
Vlasschaert C; Giles C; Hiremath S; Lanktree MB
Clin J Am Soc Nephrol; 2021 Mar; 16(3):479-486. PubMed ID: 32680914
[TBL] [Abstract][Full Text] [Related]
31. Reimagining the peer-review system for translational health science journals.
Smith EM
Clin Transl Sci; 2021 Jul; 14(4):1210-1221. PubMed ID: 33963670
[TBL] [Abstract][Full Text] [Related]
32. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Parra-Lara LG; Martinez-Arboleda JJ; Isaza-Pierotti DF; Rosso F
Int J Antimicrob Agents; 2021 Jan; 57(1):106172. PubMed ID: 33408017
[No Abstract] [Full Text] [Related]
33. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Goldman JD; Diaz G; Urba WJ
Int J Antimicrob Agents; 2021 Jan; 57(1):106174. PubMed ID: 33408020
[No Abstract] [Full Text] [Related]
34. Can we use hydroxychloroquine to treat COVID-19 now?
Chen J; Liu D; Yin L; Zhang L; Lu H
Int J Antimicrob Agents; 2021 Jan; 57(1):106173. PubMed ID: 33408016
[No Abstract] [Full Text] [Related]
35. A descriptive analysis of the data availability statements accompanying medRxiv preprints and a comparison with their published counterparts.
McGuinness LA; Sheppard AL
PLoS One; 2021; 16(5):e0250887. PubMed ID: 33983972
[TBL] [Abstract][Full Text] [Related]
36. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Saad MO
Int J Antimicrob Agents; 2021 Jan; 57(1):106171. PubMed ID: 33408024
[No Abstract] [Full Text] [Related]
37. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Dos Santos MR
Int J Antimicrob Agents; 2021 Jan; 57(1):106176. PubMed ID: 33408022
[No Abstract] [Full Text] [Related]
38. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Wambier CG
Int J Antimicrob Agents; 2021 Jan; 57(1):106175. PubMed ID: 33408021
[No Abstract] [Full Text] [Related]
39. Advanced statistical methods and designs for clinical trials for COVID-19.
Shan G; Wang W
Int J Antimicrob Agents; 2021 Jan; 57(1):106167. PubMed ID: 33408032
[No Abstract] [Full Text] [Related]
40. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
